Abstract
Introduction
COVID-19 vaccination has been rolled out in Nigeria, with low uptake often attributed to shortage of the vaccine. We set out to find out the current trend so far and to the best of our knowledge, our study is one of the early studies since the roll out in the region looking at the real situation on ground. This will guide multidisciplinary decision making at increasing uptake of the vaccine.
Methods
this is a descriptive cross-sectional study in the 5 South-Eastern States in Nigeria. A structured questionnaire was given to the members of the public to answer themselves or via the help of an interviewer. Data was analysed in SPSS and associations between variables compared using Chi square.
Results
there are 1283 respondents in this study. Of this number, only 105 (8.2%) have had at least one of the vaccine doses. Stated reasons for not having been vaccinated are side effects (n=370, 31.5%), access to a vaccination centre (n= 239, 20.4%) and belief in one’s own immunity 186 (15.5). Having a health-related degree (p-value of 0.021), non-governmental employees (p-value of 0.003), private sector employees (p-value of 0.029) and public sector employees (p-value of 0.009) are associated with relatively higher vaccination rates.
Conclusion
vaccination rate in Nigeria is still very low. Fear of side effect which is enhanced by mystical thinking is the leading factor for low turnout not just shortages. All forms of employed jobs, age and higher qualification all have significant p-values (p<0.05) and associated with higher uptake of the vaccine.
Keywords: COVID-19 virus, COVID-19 vaccine hesitancy, public health
Introduction
The low vaccination rate in Nigeria and Africa at large when compared to their richer counterparts is often attributed to vaccine shortages. The UN Secretary General has expressed his concerns regarding what he termed “vaccine distribution uneven and unfair” when speaking out on the fact that nearly 75% of the COVID-19 vaccinations worldwide has taken place in just 10 countries [1]. Even the Duke Global Health Institute did say “Will low-income countries be left behind when the COVID-19 vaccine arrives [2]. However, the real question is: is the low vaccination rate so far in Nigeria and Africa in general merely due to access to the COVID-19 vaccine? Several studies had tried to assess if people will take up the vaccine when it becomes available [3,4]. This is one of the few studies which has looked at the current trend in the ongoing vaccination so far in Nigeria. The initial roll out of the vaccine in Nigeria only invited frontline health workers and older people, however, this has been extended to all and sundry [1]. Part of this reason is due to the daily wastages in the health facilities not just in Nigeria but in most African nations [5] as vaccination turn up rate is less than what was forecasted by some fore-runner surveys which tried to see the public perception and acceptance of the COVID-19 vaccines when they become available [3,4]. There are several public health strategies to combat the pandemic including social distance, wearing face masks and adequate and effective hand washing [6]. However, vaccination is one factor which has recently proven to be a good strategy to see us out of this pandemic through its ability to reduce spread [7-9], reduce hospitalisations and severe disease [10] and significantly reduce death [11].
A study has suggested that the abundance of the vaccine is simply not enough if we truly want to maintain the targeted vaccination rate to attain herd immunity [12]. We can argue that the COVID-19 did not hit Nigeria as hard [13] as it did the UK [14] and India [15]. This does not mean we should adopt a “let´s wait and see how it goes” approach. If not for anything, we should learn from the mistakes of other nations. The REACT-1 round 12 study has proven that we are not out of the woods yet as the delta variant which was first discovered in India has replaced the UK alpha variant (Kent variant) with increased infection rates in people younger than 50 years. Thankfully, death rates are still low thanks to the protection offered by the vaccine, however, hospital admissions are gradually beginning to rise again [16]. There are two important natural (unmodifiable) factors that can be loosely associated with comparatively lower death rates and lower disease burden in this pandemic -warm weather [17] and younger age [18]. These are two factors Nigeria has in abundance no thanks to its low life expectancy of about 61 years and median age of 18.4 years [19]. However, like its natural crude deposit, it is stretching its luck far too much. The association of warmer climate to reduced spread has a very low evidence and the authors have strongly suggested that nations pursue a favourable health policy rather than “taking the easy way out” [17]. How about Long COVID-19 (having symptoms of fatigue, body aches, fever, and cough for more than 4 weeks after COVID-19 diagnosis)? About 1 million people are currently having this condition in the UK [20]. If the death rate is not that severe in Africa´s most populous nation, the sequelae of having COVID-19 alone can be debilitating. There are 3 pillars set out by the WHO in April 2020 to combating this pandemic-diagnostics, treatment, and fair vaccine distribution to all the corners of the earth. COVAX, coordinated by Gavi, is at the core to implementing the latter [21]. It set out to ensure that every nation irrespective of their resource gets a fair and equitable share of the vaccine. In a similar move, the UK has made a pledge of 100 million COVID-19 vaccines to poorer nations [22]. These are laudable. However, without strategies aimed at addressing vaccine hesitancy (refusing to be vaccinated despite the presence of vaccines) [23,24] in Nigeria, these record-breaking miles stones will not achieve its aim of vaccinating approximately 70% of the populace to gain the much needed herd immunity [12,25].
Objectives: 1) to determine the vaccination rate of the COVID-19 vaccine in the South-Eastern part of Nigeria and compare this to the national figure; 2) to understand the core reasons why the reported national vaccination rate remains lower than those of the developed nations..
Methods
Study design: this is a descriptive cross-sectional study that was conducted between the 25th of May 2021 and the 30th of June 2021 in the South-Eastern region of Nigeria.
Setting: this study was conducted in the state capitals of the 5 South-Eastern States of Nigeria namely Enugu, Anambra, Imo, Ebonyi and Abia states.
Target population, inclusion/exclusion criteria: the target population was adults 18 years and above in the five South-Eastern States of Nigeria. These were generally made of people in the public who were willing and consented to be interviewed. Because no personal identifiable markers were sought, ethical approval was not needed. Only clearly filled and legible questionnaires were included. Incompletely filled or illegible questionnaires were discarded.
Data sources: pre-validated questionnaires were used in this study. The questionnaires were distributed in-person randomly to members of the public face-to-face. Two major methods were adopted during the questionnaire distribution process: interviewer-administered and self-administered questionnaires. The participants were given the option to choose from both options. While the non-literate participants generally chose interviewer-administered questionnaires (which means the interviewer gets to read out the questions while the responder gets to supply the relevant answers), the participants who could read and write generally chose the self-administered option.
Study questionnaire development: the questionnaire was designed by the research team. The final draft was tested for validity by revered academic members. A pilot test was then run by 50 participants and feedback were collected to improve the overall delivery and ease of understanding of the questionnaire by the participants. This resulted in the final questionnaire which was presented to the participants. The results from the pilot study were discarded.
Variables: the questionnaire contained 16 questions and were divided into four sections: section 1 involved questions about patient´s demographics (eight questions in total), section 2 assessed for Knowledge about COVID-19 (three questions), section 3 assessed the participants knowledge of COVID-19 Vaccine (two questions) and then finally, section 4 reviewed whether the participants had been vaccinated or not and the reasons for each case (three questions).
Bias: we do realise that interviewers are a potential source of bias. To eliminate this, we compared data from interviewers with those from patients who filled the questionnaires themselves to see if there were any differences, and there was no statistical difference in both.
Sample size: the sampling method was random and single staged. Only respondents who agreed to fill the questionnaires were included in the study. The minimum sample size was calculated using the link below. This gave a value of about 377 at 5% precision, 95% confidence interval and 50% response distribution [26].
Statistical analysis: data analysis was done using the IBM SPSS Statistical Tool version 28. The median and percentages were the mode of univariate analysis used. Chi-square test was used to assess the differences between respondents´ willingness to receive the COVID-19 vaccines. In addition, multinomial logistic regression was performed to model the relationship between a set of predictors and the subjects´ willingness to receive COVID-19 vaccines. Statistical significance was considered at P≤0.05.
Results
Socio-demographic characteristics of the study: a total of 1283 respondents completed the questionnaire either by themselves (n= 960, 74%) or by the help of an interviewer (n= 323, 25.2%). The median age for this study is 26 to 45 years (n = 575, 44.8%). However, it is worth mentioning that the 65 years and above age group make up a paltry 60 respondents (4.7%). Majority of the respondents were females (n = 711, 55.4%), of Christian religion (n = 1223, 95.3%), reside in Nigeria (n = 1281, 99.8%), have a high school qualification as their highest level of academic qualification (n = 529, 41.2%). The number of respondents from the 5 South-Eastern States of Nigeria are not too varied with Enugu State being the highest with a total of 288 respondents (22.4%) and Imo state having the least with 190 respondents (14.8%).
Table 1 shows the knowledge of the virus and the vaccine amongst the respondents. Of the knowledge of the virus, nearly every single one of the respondents (n = 1271, 99.1%) have heard of COVID-19 virus. Also, 1179(91.7%) know that it is a viral illness. When asked to suggest one single way COVID-19 can be spread, the suggested answers were contact with an infected person (n = 806, 62.8%), contact with infected surfaces (n = 324, 25.3%), handshake (n = 63, 4.9%), not washing hand (n = 7, 0.5%), no social distance (n = 4, 0.3%), not wearing face mask (n = 11, 0.9%). Other answers were mosquito bites (n = 49, 3.8%), sexual contact (n = 16, 1.2%), and vaccine (n = 2, 0.2%). Of the knowledge of the COVID-19 vaccine, majority of the respondents (n = 1199, 93.5%) are aware that there is a vaccine for the COVID-19 virus, however greater number of the respondents (n = 820, 63.9%) do not know what kinds of vaccines are available in Nigeria. Only 105 (8.2%) of the respondents have been vaccinated. The reason given for being vaccinated was the same in all the respondents - protection of self and others. Of the unvaccinated respondents, the main reasons for not being vaccinated are side effects (n = 370, 31.5%), not knowing a vaccination centre (n = 239, 20.4%), waiting for an invitation to be vaccinated (n = 131, 11.2%), believe in one´s immunity being enough for protection (n = 239, 20.4%), and that it is a ploy to reduce the population of Africans (n = 117, 10%). Least reasons for not being vaccinated include believe that COVID-19 is unreal (68, 5.8%), the vaccine is a controlling memory chip (n=32, 2.7%) and being a nursing mother (n=3, 0.3%).
Table 1.
Variables | Frequency n (%) |
---|---|
Have you heard of COVID-19 virus? | |
Yes | 1271(99.1) |
What is COVID-19? | |
Bacteria | 46(3.6) |
Fungus | 12(0.9) |
I do not know | 49(3.8) |
Virus | 1176(91.7) |
Suggest one way the disease can be contacted | |
Not washing hands | 7(0.5) |
Contact with infected surface | 324(25.3) |
Contact with infected person | 806(62.8) |
Handshake | 63(4.9) |
Mosquito bites | 49(3.8) |
No social distance | 4(0.3) |
Not wearing face mask | 11(0.9) |
Sexual contact | 16(1.2) |
Vaccine | 2(0.2) |
Have you heard of a vaccine for COVID-19? | |
Yes | 1199(93.5) |
COVID 19 vaccine available in your area | |
I do not Know | 820(63.9) |
I know at least a vaccine type | 463(36) |
Have you been Vaccinated? | |
Yes | 105(8.2) |
If yes, why? | |
Protection of self and others | 89(100.0) |
If no, why? | |
COVID is not real | 68(5.8) |
My immunity is enough | 186(15.9) |
Waiting for invitation | 131(11.2) |
I do not know a centre | 239(20.4) |
It is a memory chip | 32(2.7) |
Religious reasons | 27(2.3) |
Nursing mother | 3(0.3) |
Side effects | 370(31.5) |
It is a ploy to reduce our population | 117(10.0) |
Table 2 is a cross table looking at how the reasons why people have not been vaccinated compared with their gender and highest level of qualification. When compared to level of academic qualification, there is a difference in the pattern of the reasons for not being vaccinated. Respondents with graduate, postgraduate and health related qualifications have four major reasons for their low vaccination turn out. For graduate holders, side effect (n = 164, 29.5%), access to a vaccine centre (n = 78, 14.4%) or the vaccine itself (n = 57, 12.4%) and believe in one´s own immunity (n= 67, 14.9%) were the major reasons topping the chart. Other reasons such as COVID-19 is not real (n= 20, 4.5%), the vaccine is a memory chip (n=10, 2.2%), religious reasons (n = 9, 2.0%), nursing mother (n = 2, 0.4%), and it is a ploy to reduce our population (n = 42, 9.4%) were the least answers in the chart. This pattern of answering is similar in people with health related and post graduate qualifications. Conversely, respondents with no formal education and only a first school living certificate answered a bit differently. For no formal education, COVID-19 is not real (n = 5, 17.9%) and side effects (n = 5, 17.9%) top the chart while other reasons are distributed nearly equally. For first school leaving certificate holders, COVID is not real (n = 16, 21.9%), belief in one´s own immunity (n = 15, 20.5%) and it is a ploy to reduce our population are the top reasons in the chart. For respondents with high school qualification, we can see a pattern of answering roughly midway between respondents with graduate education and above and people with first school leaving or no formal education. Amongst these respondents, side effects (n = 150, 29.5%), access to a vaccination centre (n = 125, 24.6%), belief in one´s own immunity (n = 80, 15.7%) and it is a ploy to reduce our population (n = 52, 10.2%) are the major reasons for not being vaccinated. When the reason for not having been vaccinated is compared with gender, there is a nearly equal proportion seen in all the fields as shown in the table below.
Table 2.
Why have you not been vaccinated? | |||||||||
---|---|---|---|---|---|---|---|---|---|
Highest level of qualification | COVID is not real | Belief in one's own immunity | I know a vaccination venue but have not been invited yet | I do not know any COVID vaccination centre | It is a memory chip | Religious reasons | Nursing mother | Side effects | It is ploy to reduce our population |
No formal education | 5(17.9%) | 4(14.3%) | 2(7.1%) | 4(14.3%) | 2(7.1%) | 2(7.1%) | 0(0.0%) | 5(17.9%) | 4(14.3%) |
First school leaving | 16(21.9%) | 15(20.5%) | 4(5.5%) | 10(13.7%) | 3(4.1%) | 2(2.7%) | 0(0.0%) | 9(12.3%) | 14(19.2%) |
High school | 24(4.7%) | 80(15.7%) | 48(9.4%) | 125(24.6%) | 16(3.1%) | 13(2.6%) | 0(0.0%) | 150(29.5%) | 52(10.2%) |
Graduate | 20(4.5%) | 67(14.9%) | 57(12.7%) | 78(17.4%) | 10(2.2%) | 9(2.0%) | 2(0.4%) | 164(36.5%) | 42(9.4%) |
Postgraduate | 2(2.4%) | 15(17.9%) | 12(14.3%) | 19(22.6%) | 1(1.2%) | 1(1.2%) | 0(0.0%) | 29(34.5%) | 5(6.0%) |
Health related degree | 1(3.2%) | 5(16.1%) | 8(25.8%) | 3(9.7%) | 0(0.0%) | 0(0.0%) | 1(3.2%) | 13(41.9%) | 0(0.0%) |
Cumulative | 68(5.8%) | 186(15.9%) | 131(11.2%) | 239(20.4%) | 32(2.7%) | 27(2.3%) | 3(0.3%) | 370(31.5%) | 117(10.0%) |
Gender | |||||||||
Female | 32(4.9%) | 118(18.1%) | 72(11.0%) | 126(19.3%) | 22(3.4%) | 16(2.5%) | 3(0.5%) | 202(30.9%) | 62(9.5%) |
Male | 36(6.9%) | 68(13.1%) | 59(11.3%) | 113(21.7%) | 10(1.9%) | 11(2.1%) | 0(0.0%) | 168(32.3%) | 55(10.6%) |
Cumulative | 68(5.8%) | 186(15.9%) | 131(11.2%) | 239(20.4%) | 32(2.7%) | 27(2.3%) | 3(0.3%) | 370(31.5%) | 117(10.0%) |
On bivariate analysis, Table 3 gives a summary of the factors playing a role in the vaccination rates in the South-Eastern Nigeria. Age (p-value of 0.003), level of qualification (p<0.001) and place of work (p = 0.001) play a significant role at determining vaccination rates. One limitation of this study is that employs the services of interviewers to help ask the questions in situations where respondents are not able to do so themselves. However, mode of collection (p = 0.420) was not associated with any significance which is expected to rule out bias from the field agents who helped with collection of data. Gender, religion, place of residence, all have non-significant P-values and do not play a role at determining who gets vaccinated or not.
Table 3.
Have you been vaccinated? | No | Yes | P-value | |
---|---|---|---|---|
Mode of collection | Interviewer | 300 (92.9) | 23 (7.1) | 0.420 |
self | 878(91.5) | 82(8.5) | ||
Age | ||||
18 - 25 | 437(95.6) | 20(4.4) | 0.003 | |
26 - 45 | 517(89.9) | 58(10.1) | ||
46 - 64 | 171(89.5) | 20(10.5) | ||
65 and above | 53(88.3) | 7(11.7) | ||
Gender | ||||
Female | 657(92.4) | 54(7.6) | 0.391 | |
Male | 521(91.1) | 51(8.9) | ||
Religion | ||||
Christianity | 1121(91.7) | 102(8.3) | 0.789 | |
Islam | 32(94.1) | 2(5.9) | ||
Traditional | 20(95.2) | 19(4.8) | ||
Others | 5(100.0) | 0(0.0) | ||
Country of residence | ||||
Others | 2(100.0) | 0(0.0) | 0.673 | |
Nigeria | 1176(91.8) | 105(8.2) | ||
State of residence | ||||
Abia | 256(92.8) | 20(7.2) | 0.219 | |
Anambra | 250(92.3) | 21(7.7) | ||
Ebonyi | 243(94.2) | 15(5.8) | ||
Enugu | 256(88.9) | 32(11.1) | ||
Imo | 173(91.1) | 17(8.9) | ||
Highest level of qualification | ||||
First school leaving | 72(94.7) | 4(5.3) | <0.001 | |
Graduate | 459(91.1) | 45(8.9) | ||
High school | 501(94.7) | 28(5.3) | ||
MBBS | 32(72.7) | 12(27.3) | ||
No formal education | 29(93.5) | 2(6.5) | ||
Postgraduate | 85(85.9) | 14(14.1) | ||
Place of work | ||||
NGO employee | 32(80.0) | 8(20.0) | <0.001 | |
Private sector employee | 142(89.3) | 17(10.7) | ||
Public sector employee | 246(85.4) | 42(14.6) | ||
Retired | 2(100.0) | 0(0.0) | ||
Self employed | 262(93.9) | 17(6.1) | ||
Student | 386(95.5) | 18(4.5) | ||
Unemployed | 108(97.3) | 3(2.7) |
On multiple logistic regression analysis (Table 4), having a health-related degree (p-value of 0.021), non-governmental employees (p-value of 0.003), private sector employees (p-value of 0.029) and public sector employees (p-value of 0.009) all have significant differences and associated with relatively higher vaccination rates.
Table 4.
Have you been Vaccinated? | Yes | ||
---|---|---|---|
Std. error | P-value | 95% C. I | |
Age | |||
65 and above | Ref | ||
18 - 25 | 0.529 | 0.134 | 0.783 - 6.219 |
26 - 45 | 0.447 | 0.364 | 0.625 - 3.602 |
46 - 64 | 0.483 | 0.577 | 0.508 - 3.373 |
Gender | |||
Male | Ref | ||
Female | 0.215 | 0.519 | 0.753 -1.752 |
Highest level of educational qualification | |||
Postgraduate | Ref | ||
First school | 0.633 | 0.521 | 0.434 - 5.185 |
Graduate | 0.335 | 0.349 | 0.710 - 2.637 |
High school | 0.415 | 0.773 | 0.500 - 2.542 |
Health related degree | 0.460 | 0.021 | 0.141 - 0.852 |
No formal education | 0.838 | 0.929 | 0.209 - 5.567 |
Place of work | |||
Unemployed | Ref | ||
NGO employee | 0.728 | 0.003 | 0.029 - 0.497 |
Private sector employee | 0.656 | 0.029 | 0.066 - 0.864 |
Public sector employee | 0.638 | 0.009 | 0.054 - 0.662 |
Self employed | 0.641 | 0.205 | 0.126 - 1.559 |
Student | 0.670 | 0.323 | 0.139 - 1.919 |
Discussion
Although COVID-19 is relatively a new disease and most of our learning has been from our own failures in the pandemic, some important facts are nearly certain at this point-we know that vaccine works. Vaccination reduces infection rate [7-9], reduces hospitalisation in COVID-19 related respiratory syndromes [10] and death rates from COVID-19 [11]. This study has identified a vaccination rate of 8.2% amongst the respondents (n = 105/1283, 8.2%) for people who have had at least one of the jabs. This is clearly less than the 70% target by the Nigerian federal government [1]. The official number of people who have had at least one of the COVID-19 jabs in Nigeria stands at 2.23 million as of the 23rd of June 2021 according to our world in data. This represents about 0.1% of the populace [13]. This contrasts to those of the developed nations such as the UK where nearly 81.9% of the population has had one of the vaccines and 59.8% has had both in the same period [14]. About 95% of the respondents have heard of COVID-19 while about 90 percent are aware of a vaccine for COVID-19 virus. Some studies put the knowledge of COVID-19 virus at a similar figure [27,28]. The truth is that most people want to be vaccinated [3,25]. How come the vaccine uptake is not as rapid as one would expect?
In this study, concerns about side effects (n= 370, 31.5%), access to a vaccination centre (n = 239, 20.4%), belief in one´s immunity (n = 186, 15.9%) and waiting for invitation to be vaccinated (n = 131, 11.2%), are the most important factors identified. Side effects from vaccine has been a recognised driving factor to vaccine hesitancy [29-31]. This study has shown that the level of one´s educational qualification plays a significant role in their tendency to receive the COVID-19 vaccine with higher vaccination rates amongst people with MBBS (n = 12, 27%), graduate (n = 45, 8.9%) and post graduate qualifications (n = 14, 14.1%) when compared to people with only high school (n = 28, 5.3%), first school leaving (n = 4, 5.3%) or no formal education (n=2, 6.5%). This is the case in a similar study [30]. Also, people in employed jobs (NGOs, private sector, and public sector) have higher vaccination rates than people who are self-employed, unemployed or students the study has shown. This contrasts with a finding in Jordan where employed respondents were less likely to be vaccinated [32]. The older the individual, the more likely they are to accept a vaccine. This is reflected in similar studies [30-33]. How do we get out of the situation and increase the uptake in Nigeria? The internet and social media are a major source of information for people these days and often misinformation cannot be rule out [34,35]. It is suggested that the authorities should channel people to a more evidence based source of information such as television and government website [36]. Also engaging with the people through their community and church leaders will help in strengthening trust amongst the populace [37]. It is important to address the concerns of the local people rather than dispelling their concerns as merely superstitious and senseless [29]. Although COVAX and the UK have pledged their commitment in vaccinating Africa, local production of the vaccine will tackle the issue of access [38]. The AstraZeneca and Johnson & Johnson vaccines are the main vaccines in Nigeria now [1]. With the whole media campaign which makes it appear as though the AstraZeneca is an inferior brand given the lower efficacy of 62.1% compared to the Pfizer/BioNTech efficacy of 95% [39] plus the side effect profile (blood clots) of AstraZeneca vaccine, people in Nigeria may see this as a battle of them versus us as AstraZeneca is the main brand in Nigeria. COVAX should ensure that all vaccine brands are made available to every nation.
A study conducted in Denmark and Norway showed a very marginal increase in cerebral venous thrombosis (11 cases per 100,000 people) with AstraZeneca vaccines compared to the normally expected rate (2.5 cases per 100,000). It, however, did not find any excess in arterial events (heart attacks or strokes). They went further to support the EU and UK medical regulator decisions that the side effects are too low and that the benefits far exceeded the risks and countries who refused AstraZeneca vaccines would have prevented some unnecessary deaths [40]. Landmark studies such as these, quite frankly do not get media attention, even when they need to be made available to governments and ordinary people all over the world to help address the fears and concerns that people have. Early trials on the COVID-19 vaccines in Africa raised some ethical issues amongst some Africans who think Africans are only being used. However, this is not the case as only 2% of all vaccine trials take place in Africa [41]. These facts need to be made very clear to people. Also, all over Africa, there seems to be a band wagoning in the decisions of the leaders who played herd mentality to their “colonialist” counterparts. Hence, it was not about what works for Abuja but what London says. We went into a lockdown, with no reason, no strategy, and no economic cushioning as was the case in the west. And like its inception, we only relaxed things when London relaxed things [42]. This made many to lose confidence in anything the government had to say further [28]. We need consistencies in policies and strategies that reflect local need.
Limitation of this study: interviewers helped in the filling of the questionnaire in 323 (25.2%) respondents with the possibility of introducing bias.
Conclusion
The low vaccination rate in Nigeria is often loosely associated with shortage even when the situation on ground suggests differently. The fear of side effects is the main reason reducing the uptake of the vaccine not just shortages. We found a vaccination rate of 8% in this study. Factors associated with higher uptake of the vaccine include: all forms employed jobs (non-governmental employees, p-value of 0.003, private sector employees, p-value of 0.029, public sector employees, p-value of 0.009), age (with higher vaccination rates in the 26-64-year-old group, p-0.003), higher qualification (p<0.001). To boost the vaccination rate, education and awareness campaign will be very useful.
What is known about this topic
Most Nigerians (75%) showed willingness to accept the COVID-19 vaccines before its arrival. However, government data shows a 0.1% vaccination;
The low vaccination is attributed to poverty and vaccine shortages in Nigeria (DGHI);
Vaccination reduces infection rate, reduces hospitalisation in COVID-19 related respiratory syndromes and death rates from COVID-19. This study has identified a vaccination rate of 8.2% amongst the respondents (n = 105/1283, 8.2%) for people who have had at least one of the jabs.
What this study adds
The low vaccination rate in Nigeria is mainly because people are scared about side effects fuelled by mystical thinking not necessarily due to shortages. This needs to be addressed if we truly want to vaccinate Africa in this pandemic. Individuals with higher educational qualification and people in employed jobs are the main groups who tend to be vaccinated. We can argue that these two groups of individuals have better access to objective information. This shows that education will be a useful strategy to boost vaccination.
Footnotes
Cite this article: Onyekachi Ezekiel Ekowo et al. A cross-sectional regional study looking at the factors responsible for the low COVID-19 vaccination rate in Nigeria. Pan African Medical Journal. 2022;41(114). 10.11604/pamj.2022.41.114.30767
Competing interests
The authors declare no competing interests.
Authors’ contributions
OEE conceptualised the topic, wrote the abstract, the introduction, result, discussion, and conclusion. CM wrote the methods. RCI, CMO, IC, AFO, STE, II, UDN and OCN were involved in data collection. All the authors have read and agreed to the final manuscript.
References
- 1.UN Nigeria: COVID-19 vaccine rollout kicks off in Africa's most populous country. Accessed June 30 2021. [Google Scholar]
- 2.DGHI Will low income countries be left behind when the COVID-19 vaccines arrives. Accessed June 15 2021 Adebisi YA, Alaran AJ, Bolarinwa OA, Akande-Sholabi W, Lucero-Prisno DE. When it is available, will we take it? Social media users' perception of hypothetical COVID-19 vaccine in Nigeria. Pan Afr Med J. 2021 Mar 2;38:230.
- 3.Ekwebelem OC, Yunusa I, Onyeaka H, Ekwebelem NC, Nnorom-Dike O. COVID-19 vaccine rollout: will it affect the rates of vaccine hesitancy in Africa? Public Health. 2021 Aug;197:e18–e19. doi: 10.1016/j.puhe.2021.01.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.CNN African countries have struggled to secure enough COVID-19 vaccines. So why are thousands of doses going to waste? Accessed June 20 2021.
- 5.CDC COVID-19: how to protect yourself and others. Accessed June 20 2021. [Google Scholar]
- 6.Amit S, Regev-Yochay G, Afek A, Kreiss Y, Leshem E. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. Lancet. 2021 Mar 6;397(10277):875–7. doi: 10.1016/S0140-6736(21)00448-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Levine-Tiefenbrun M, Yelin I, Katz R, Herzel E, Golan Z, Schreiber L, et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med. 2021 May;27(5):790–2. doi: 10.1038/s41591-021-01316-7. [DOI] [PubMed] [Google Scholar]
- 8.Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 Infection among health care personnel, first responders, and other essential and frontline workers-Eight U.S. locations, December 2020-March 2021. MMWR Morb Mortal Wkly Rep. 2021 Apr 2;70(13):495–500. doi: 10.15585/mmwr.mm7013e3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Public Health England . 2021. Feb 18, Weekly national influenza and COVID-19 surveillance report: week 7 report (up to week 6 data) Accessed 19 June 2021. [Google Scholar]
- 10.National Records of Scotland Deaths involving COVID-19 week 6: 8 Feb-14 Feb. Accessed June 19 2021. [Google Scholar]
- 11.Schaffer DeRoo S, Pudalov NJ, Fu LY. Planning for a COVID-19 vaccination program. JAMA. 2020 Jun 23;323(24):2458–2459. doi: 10.1001/jama.2020.8711. [DOI] [PubMed] [Google Scholar]
- 12.NCDC COVID-19 Nigeria. Accessed June 23 2021.
- 13.GOV UK Vaccinations in United Kingdom. Accessed June 23 2021.
- 14.WHO . COVID-19 situation report: India. Accessed July 23 2021. [Google Scholar]
- 15.Riley S, Wang H, Eales O, Haw D, Walters C, Ainslie K, et al. Imperial College. REACT-1 round 12 report: resurgence of SARS-CoV-2 infections in England associated with increased frequency of the Delta variant. Accessed July 23, 2021. [Google Scholar]
- 16.Mecenas P, Bastos R, Vallinoto ACR, Normando D. Effects of temperature and humidity on the spread of COVID-19: a systematic review. PLoS One. 2020 Sep 18;15(9):e0238339. doi: 10.1371/journal.pone.0238339. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.WHO People of all ages can be infected by the COVID-19 virus. Accessed June 23 2021.
- 18.Statista African countries with the lowest median age as of 2021. Accessed June 15 2020.
- 19.ONS . Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 1 April 2021. Accessed June 23, 2021. [Google Scholar]
- 20.Gavi: The Vaccine Alliance COVAX explained. Accessed June 20 2021. [Google Scholar]
- 21.The Guardian UK to give 100 million COVID vaccine doses to poorer countries within a year. Accessed June 20 2021.
- 22.Dubé E, Gagnon D, Ouakki M, Bettinger JA, Guay M, Halperin S, et al. Understanding vaccine hesitancy in Canada: results of a consultation study by the Canadian Immunization Research Network. PLoS One. 2016;11(6):e0156118. doi: 10.1371/journal.pone.0156118. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.MacDonald NE. Vaccine hesitancy: definition, scope and determinants. Vaccine. 2015 Aug 14;33(34):4161–4. doi: 10.1016/j.vaccine.2015.04.036. [DOI] [PubMed] [Google Scholar]
- 24.Samarasekera U. Feelings towards COVID-19 vaccination in Africa. Lancet Infect Dis. 2021 Mar;21(3):324. doi: 10.1016/S1473-3099(21)00082-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Raosoft Sample size calculator. Accessed July 14 2021.
- 26.Ilesanmi O, Afolabi A, Uchendu O. The prospective COVID-19 vaccine: willingness to pay and perception of community members in Ibadan, Nigeria. PeerJ. 2021;9:e11153. doi: 10.7717/peerj.11153. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Oleribe O, Ezechi O, Osita-Oleribe P, Olawepo O, Musa AZ, Omoluabi A, et al. Public perception of COVID-19 management and response in Nigeria: a cross-sectional survey. BMJ Open. 2020;10(10):e041936. doi: 10.1136/bmjopen-2020-041936. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Razai MS, Chaudhry UAR, Doerholt K, Bauld L, Majeed A. COVID-19 vaccination hesitancy. BMJ. 2021;373:n1138. doi: 10.1136/bmj.n1138. [DOI] [PubMed] [Google Scholar]
- 29.Robertson E, Reeve KS, Niedzwiedz CL, Moore J, Blake M, Green M, et al. Predictors of COVID-19 vaccine hesitancy in the UK household longitudinal study. Brain Behav Immun. 2021 May;94:41–50. doi: 10.1016/j.bbi.2021.03.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Soares P, Rocha JV, Moniz M, Gama A, Laires PA, Pedro AR, et al. Factors associated with COVID-19 vaccine hesitancy. Vaccines (Basel) 2021;9(3):300. doi: 10.3390/vaccines9030300. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.El-Elimat T, AbuAlSamen MM, Almomani BA, Al-Sawalha NA, Alali FQ. Acceptance and attitudes toward COVID-19 vaccines: a cross-sectional study from Jordan. PLoS One. 2021;16(4):e0250555. doi: 10.1371/journal.pone.0250555. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Malik AA, McFadden SM, Elharake J, Omer SB. Determinants of COVID-19 vaccine acceptance in the US. E Clinical Medicine. 2020 Sep;26:100495. doi: 10.1016/j.eclinm.2020.100495. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Guidry JP, Carlyle K, Messner M, Jin Y. On pins and needles: how vaccines are portrayed on Pinterest. Vaccine. 2015 Sep 22;33(39):5051–6. doi: 10.1016/j.vaccine.2015.08.064. [DOI] [PubMed] [Google Scholar]
- 34.Kanyike AM, Olum R, Kajjimu J, Ojilong D, Akech GM, Nassozi DR, et al. Acceptance of the coronavirus disease-2019 vaccine among medical students in Uganda. Trop Med Health. 2021 May 13;49(1):37. doi: 10.1186/s41182-021-00331-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Chadwick A, Kaiser J, Vaccari C, Freeman D, Lambe S, Loe BS, et al. Online social endorsement and COVID-19 vaccine hesitancy in the United Kingdom. Social Media + Society. 2021;7(2):20563051211008817. [Google Scholar]
- 36.Peterson P, McNabb P, Maddali SR, Heath J, Santibañez S. Engaging communities to reach immigrant and minority populations: the Minnesota Immunization Networking Initiative (MINI), 2006-2017. Public Health Rep. 2019 May/Jun;134(3):241–8. doi: 10.1177/0033354919834579. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Nachega JB, Sam-Agudu NA, Masekela R, van der Zalm MM, Nsanzimana S, Condo J, et al. Addressing challenges to rolling out COVID-19 vaccines in African countries. Lancet Glob Health. 2021 Jun;9(6):e746–e8. doi: 10.1016/S2214-109X(21)00097-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.The Telegraph UK How the Moderna. AstraZeneca Pfizer and other COVID vaccines compare. Accessed June 23, 2021.
- 39.Pottegård A, Lund LC, Karlstad Ø, Dahl J, Andersen M, Hallas J, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ. 2021;373:n1114. doi: 10.1136/bmj.n1114. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Makoni M. COVID-19 vaccine trials in Africa. Lancet Respir Med. 2020 Nov;8(11):e79–e80. doi: 10.1016/S2213-2600(20)30401-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Rubini L. Can social distancing work in low income countries? 2020. Accessed May 27, 2020.
- 42.Rubini L. Can social distancing work in low income countries? 2020. Accessed May 27, 2020.